Study ID: TV48125-CNS-30088
Study Title
- A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine
Teva Identifier
- TV48125-CNS-30088
ClinicalTrials.gov Identifier
- NCT05458011
Study Status
- Recruiting
Trial Condition(s)
- Migraine Headache
Interventions
- Drug: Fremanezumab | Drug: Placebo
Study Description
The primary Objective is to demonstrate the efficacy of fremanezumab administered as monthly and quarterly subcutaneous (sc) injections to adult Chinese participants with migraine. The secondary Objectives are to further demonstrate the efficacy of fremanezumab administered as monthly and quarterly sc injections and to evaluate the safety and tolerability of fremanezumab administered as monthly and quarterly sc injections. The total study duration for participants is planned to be approximately 9 months. The study will consist of a screening visit, a baseline period (4 weeks), a 12-week double-blind treatment period, a 12-week open-label treatment period, and a follow-up period lasting approximately 3 months after the last dose of treatment.
Key Participation Requirements
Gender
- Female, Male
Age Range
- Adult
Phase
- Phase 3
Study Type
Interventional
Location - Where to Participate
You may contact 1-888-483-8279 or email USMedInfo@tevapharm.com to obtain more information about study locations.
